Leptin, Antagonist, Triple Mutant, Recombinant, Rat (Ob, Obese Protein, Obesity Factor)

Leptin inhibits food intake and stimulates energy expenditure. Leptin also has thermogenic actions and regulates enzymes of fatty acid oxidation. Severe hereditary obesity in rodents and humans is caused by defects in leptin production. In addition to its critical role in the physiologic regulation of body weight leptin has a variety of other physiologic and pathologic functions resembling those of cytokines. These functions include the regulation of hematopoiesis, angiogenesis, wound healing, inflammation, and immune responses.\n\nRecombinant rat leptin, one polypeptide chain containing 146aa and additional Ala at the N-terminus and having a molecular mass of ~16kD, rLEP was mutated, resulting in L39A/D40A/F41A mutant.\n\nAmino Acid Sequence: \nThe sequence of the first five N-terminal amino acids was determined and was found to be Ala-Val-Pro-Ile-Gln\n\nDimers and Aggregates: \n<1% as determined by silver-stained SDS-PAGE gel analysis.\n\nBiological Activity: \nrLEP is fully biologically active when compared to standards. The ED50, calculated by the leotub-dependent stimulation of human OB-R transfected murine BAF/3 indicator cells is 0.35-0.06ng/ml.\n\nProtein Content: \nProtein quantization was carried out by UV spectroscopy at 280nm using the absorbency value of 0.201 as the extinction coefficient for a 0.1% (1mg/ml) solution at pH 8.0. This value is calculated by the PC GENE computer analysis program of protein sequences (IntelliGenetics).\n\nStorage and Stability:\nLyophilized powder may be stored at 4 degrees C for short-term only. Reconstitute to nominal volume by adding sterile dH2O, 0.1% HSA or BSA and store at -20 degrees C. Reconstituted product is stable for 12 months at -20 degrees C. For maximum recovery of product, centrifuge the original vial after thawing and prior to removing the cap. Further dilutions can be made in assay buffer.

Prices direct from United States Biological

Quick response times

Exclusive Biosave savings/discounts

SPECIFICATIONS

Catalog Number

L1670-16A

Size

20ug

Form

Supplied as a sterile-filtered, lyophilized powder in 0.003mM NaHCO3. Reconstitute in sterile dH2O, 0.1% HSA or BSA to (same/more than) 0.1mg/ml.

Purity

(same/more than)95% by RP-HPLC, FPLC, or reducing/non-reducing SDS-PAGE Silver Stain. Chromatographically purified. .Endotoxin: (same/less than) 0.1ng/ug (IEU/ug).

References

1. Relationship between soluble leptin receptor, leptin, lipid profiles and anthropometric parameters in overweight and obese Thai subjects. J Med Assoc Thai 2005 Feb;88(2):220-7. 2. Plasma leptin concentration increases early during highly active antiretroviral therapy for acquired immunodeficiency syndrome, independent of body weight. J Endocrinol Invest 2005 Mar;28(3):RC1-3. 3. The roles of leptin and adiponectin: a novel paradigm in adipocytokine regulation of liver fibrosis and stellate cell biology. Am J Pathol 2005 Jun;166(6):1655-69. 4. Leptin therapy does not affect inflammatory markers. J Clin Endocrinol Metab 2005 Jun;90(6):3803; author reply 3803. 5. Leptin inhibits apolipoprotein M transcription and secretion in human hepatoma cell line, HepG2 cells. Biochim Biophys Acta 2005 May 15;1734(2):198-202. 6. A retinoid X receptor antagonist, HX531, improves leptin resistance without increasing plasma leptin level in KK-Ay mice under normal dietary conditions. Metabolism 2005 May;54(5):573-8.